PL415644A1 - Concentration of iron in blood as a risk factor for cancers in women after the age of 50 - Google Patents
Concentration of iron in blood as a risk factor for cancers in women after the age of 50Info
- Publication number
- PL415644A1 PL415644A1 PL415644A PL41564415A PL415644A1 PL 415644 A1 PL415644 A1 PL 415644A1 PL 415644 A PL415644 A PL 415644A PL 41564415 A PL41564415 A PL 41564415A PL 415644 A1 PL415644 A1 PL 415644A1
- Authority
- PL
- Poland
- Prior art keywords
- concentration
- iron
- risk
- serum
- age
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title abstract 12
- 229910052742 iron Inorganic materials 0.000 title abstract 6
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 239000008280 blood Substances 0.000 title 1
- 210000004369 blood Anatomy 0.000 title 1
- 210000002966 serum Anatomy 0.000 abstract 5
- 239000012620 biological material Substances 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 239000012472 biological sample Substances 0.000 abstract 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
W zgłoszeniu ustalono, że występuje korelacja między stężeniem żelaza w surowicy a ryzykiem raków u kobiet po 50 roku życia. Przedmiotem zgłoszenia jest sposób określania ryzyka raka, charakteryzuje się tym, że obejmuje ocenę stężenia żelaza w próbce biologicznej badanej kobiety, przy czym stężenie żelaza wskazuje znacząco zwiększone/obniżone ryzyko rozwoju raków u kobiet po 50 roku życia: - przy stężeniu żelaza w surowicy < 785 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy) ryzyko jest zwiększone; - przy stężeniu żelaza w surowicy 975-11025 µg/l (lub stężeniu w dowolnym materiale biologicznym odpowiadającym stężeniu w surowicy) ryzyko jest obniżone.The report found that there is a correlation between serum iron levels and cancer risk in women over 50 years of age. The subject of the application is a method for determining the risk of cancer, characterized by the fact that it includes the assessment of iron concentration in the biological sample of the examined woman, while the concentration of iron indicates a significantly increased / reduced risk of developing cancers in women over 50: - with serum iron <785 µg / l (or concentration in any biological material corresponding to serum concentration) the risk is increased; - at a serum iron concentration of 975-11025 µg / l (or concentration in any biological material corresponding to the serum concentration) the risk is reduced.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415644A PL415644A1 (en) | 2015-12-30 | 2015-12-30 | Concentration of iron in blood as a risk factor for cancers in women after the age of 50 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL415644A PL415644A1 (en) | 2015-12-30 | 2015-12-30 | Concentration of iron in blood as a risk factor for cancers in women after the age of 50 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL415644A1 true PL415644A1 (en) | 2017-07-03 |
Family
ID=59201416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL415644A PL415644A1 (en) | 2015-12-30 | 2015-12-30 | Concentration of iron in blood as a risk factor for cancers in women after the age of 50 |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL415644A1 (en) |
-
2015
- 2015-12-30 PL PL415644A patent/PL415644A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016007348A2 (en) | specific binding member that binds to human epidermal growth factor 2 receptor (her2) for use in a patient cancer treatment method, a patient cancer treatment method, a patient cancer identification method , method to predict cancer response | |
| MX389083B (en) | Radiolabeled anti-PD-L1 antibodies for immuno-PET imaging. | |
| MX2021006791A (en) | Methods and compositions for detecting misfolded proteins. | |
| BR112016007864A2 (en) | Method for cancer prognosis and metastasis treatment | |
| WO2017062496A3 (en) | Anti-sas1b antibodies, associated methods of use, and compositions and methods for detecting and treating cancer | |
| MY187050A (en) | Cancer cell-specific antibody, anticancer agent, and cancer testing method | |
| NZ722492A (en) | Specific biomarker set for non-invasive diagnosis of liver cancer | |
| MX377026B (en) | BIOMARKERS FOR DISEASE PROGRESSION IN MELANOMA. | |
| BR112016017926A2 (en) | Assay for human periostin | |
| MX384485B (en) | EARLY DETECTION OF PREECLAMPSIA. | |
| MX2015015023A (en) | Method for determining free copper. | |
| MX384636B (en) | METHOD FOR DETECTING NEUTRALIZING ANTIBODIES AGAINST RECOMBINANT HUMAN INSULIN IN HUMAN SERUM. | |
| EP4253960A3 (en) | Materials and methods for assessing cancer risk and treating cancer | |
| PL415644A1 (en) | Concentration of iron in blood as a risk factor for cancers in women after the age of 50 | |
| CO2021004035A2 (en) | Immunogenetic Cancer Screening Assay | |
| PL414266A1 (en) | Concentration of selenium in blood as a risk factor for cancers in women | |
| PL414265A1 (en) | Concentration of copper in blood as a risk factor for extramammary breast cancers in women | |
| PL415636A1 (en) | Concentration of iron in blood as a risk factor for cancers in men | |
| PL406989A1 (en) | Profile of micro RNA in blood as the test for detecting lung cancer | |
| PL415634A1 (en) | Concentration of selenium in blood as a risk factor for cancers in men | |
| PL414267A1 (en) | Concentration of iron in blood as a risk factor for cancers in women who are carriers of a mutation in BRCA1 gene | |
| PL415632A1 (en) | Concentration in blood and changes within IL6 gene as risk factors for cancers in women | |
| PL439314A1 (en) | Method for determining the risk of cancers in women, depending on concentration of cadmium in the blood | |
| PL415639A1 (en) | Concentration of iron in blood and changes within SEP15 gene as risk factors for cancers in women | |
| PL439315A1 (en) | The method of determining the risk of cancer in women depending on the concentration of selenium in the blood |